Loading insider details...
Beta
Latest Form 4 (Oct 19, 2026): Conversion of 610,759 CTY shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 19, 2026 | CITY THERAPEUTICS, INC. (CTY) | Conversion | 610,759 | n/a |
| Jul 6, 2026 | TAKEDA PHARMACEUTICAL CO LTD (TAK) | Grant/Award | 3,800 | n/a |
| Jun 25, 2026 | Kymera Therapeutics, Inc. (KYMR) | Grant/Award | 6,068 | n/a |
| Jun 10, 2026 | Rapport Therapeutics, Inc. (RAPP) | Grant/Award | 15,200 | n/a |
| Jun 5, 2026 | Beam Therapeutics Inc. (BEAM) | Grant/Award | 19,676 | n/a |
| May 4, 2026 | Hemab Therapeutics Holdings, Inc. (COAG) | Conversion | 17,974 | n/a |
| Jun 27, 2025 | Kymera Therapeutics, Inc. (KYMR) | Grant/Award | 16,000 | n/a |
| Jun 18, 2025 | Rapport Therapeutics, Inc. (RAPP) | Grant/Award | 21,850 | n/a |
| Jun 6, 2025 | Beam Therapeutics Inc. (BEAM) | Grant/Award | 33,662 | n/a |
| Jun 20, 2024 | Kymera Therapeutics, Inc. (KYMR) | Grant/Award | 16,000 | n/a |